Current through Register Vol. 49, No. 6, March 15, 2024
(1) Pursuant to authority granted to the
board by section 334.100.2(4)(f), RSMo, the board declares the use of Human
Chorionic Gonadotropin (HCG) on a patient is of no medical or osteopathic value
in weight loss or the treatment of obesity.
(2) The board shall not seek disciplinary
action against a licensee based solely on the use of HCG for weight loss and
obesity treatment if the licensee has the patient sign the Informed Consent for
HCG form, included herein, before beginning the non-approved
use of HCG on a patient.
Informed Consent for Human Chorionic
Gonadotropin (HCG)
Patient's Name:
_______________________________________
Address: _______________________________________
_______________________________________
Age: _______ Sex: ___Male ____Female
Name and Address of Treating Physician:
Malignancy, disease, illness or physical condition diagnosed
for medical treatment with HCG:
My physician has explained to me and I fully
understand:
(a) that the FDA package
insert for HCG states, "HCG has not been demonstrated to be effective
adjunctive therapy in the treatment of obesity. There is no substantial
evidence that it increases weight loss beyond that resulting from caloric
restriction, that it causes a more attractive or 'normal' distribution of fat,
or that it decreases the hunger and discomfort associated with
calorie-restricted diets";
(b)
because of the potential for side effects, the FDA package insert suggests that
HCG should be used with caution in patients with certain conditions, including
cardiac diseases, renal disease, epilepsy, migraine and asthma;
(c) that the American Society of Bariatric
Physicians has issued a position statement that the use of HCG for weight loss
is not recommended. Bariatric medicine is the field of medicine which
specializes in the evaluation and treatment of overweight people through
medical management;
(d) prior to
prescribing medication for weight loss a physician should obtain a complete
medical history, perform a comprehensive physical examination of the patient
and order appropriate tests to include, but not limited to, an EKG and tests of
thyroid function, liver function, and kidney function to confirm that there are
no medical conditions which are a contraindication to the use of HCG;
(e) that there are no peer-reviewed studies
supporting the use of HCG in weight loss;
(f) that the federal government and most
insurance companies do not pay for or reimburse for treatment with
HCG;
(g) that the Missouri State
Board of Registration for the Healing Arts has monitored the development of the
scientific literature on HCG and has concluded that HCG has been
authoritatively demonstrated to be ineffective in the
treatment of obesity and weight loss;
(h) that the Missouri State Board of Registration for
the Healing Arts has determined that the use of HCG for obesity or weight loss
by Missouri citizens may be harmful to their health;
(i) as of December 6, 2011, the FDA has
prohibited the sale of "homeopathic" and over the counter HCG diet products and
declared them fraudulent and illegal;
(j) that neither the American Medical
Association, the American Osteopathic Association, nor any other recognized
independent medical association recommend the use of HCG for the treatment of
obesity or weight loss;
(k) that
the Missouri State Board of Registration for the Healing Arts strongly
recommends that Missouri citizens not undergo HCG treatment for obesity or
weight loss; and
(l) that treatment
with HCG may not begin until three business days have expired after the date of
my execution of this informed consent.
__________________________________
______________________
Physician's Signature Date
I have read and understand the above. Notwithstanding having
read and understood the above, I hereby elect to undergo treatment with
HCG.
__________________________________
________________________
Patient's Signature Date
*Original authority: 334.100, RSMo 1939, amended 1945,
1959, 1963, 1974, 1976, 1979, 1981, 1983, 1984, 1986, 1987, 1989, 1990, 1993,
1997, 2004, 2010, 2011 and 334.125, RSMo 1959, amended 1993,
1995.
